Roche Gears Up To Launch Actemra; Lines Up More Clinical Research In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Unperturbed by the spate of patent litigations, Swiss drug maker Roche is planning to bring into India Actemra (tocilizumab), its biological therapy indicated for the treatment of rheumatoid arthritis in adults and children
You may also be interested in...
Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.
Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.
Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News
Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.